Label Image (Lbl500907391)
Tadalafil Tablet, Film Coated
Product Images NDC 50090-7391
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-7391). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Spl-tadalafil-figure-1 (Spl Tadalafil Figure 1)
Spl-tadalafil-figure-2 (Spl Tadalafil Figure 2)
This is a comparison of standing systolic blood pressure and supine systolic blood pressure measurements taken at different time points after the administration of Tadalafil 20 mg & doxazosin 8 mg versus Placebo & doxazosin 8 mg. The data seems to be related to a study or clinical trial evaluating the effects of these medications on blood pressure.*
Spl-tadalafil-figure-3 (Spl Tadalafil Figure 3)
This is a description of a study related to blood pressure and medication administration. It involves the comparison of different treatment regimens for systolic blood pressure. The study includes the administration of 20 mg of tadalafil and 8 mg doxazosin at different times, as well as a placebo group. The chart suggests variations in systolic blood pressure readings at different time intervals after the medication is given.*
Spl-tadalafil-figure-4 (Spl Tadalafil Figure 4)
This is a graph showing the Plasma Tadalafil Concentration in micrograms per liter over a period of 120 hours. It includes data points for a single 20-mg tadalafil dose, a single 5-mg tadalafil dose, and a once-daily 5-mg tadalafil dose following 5 consecutive days of administration. The graph demonstrates how the concentration of tadalafil changes over time.*
Spl-tadalafil-figure-5 (Spl Tadalafil Figure 5)
This is a comparison of the change from the baseline in IPSS total score between Tadalafil 5 mg and Placebo, with statistical significance (p<0.01) indicated. The duration of treatment in weeks is also listed for reference.*
Spl-tadalafil-figure-6 (Spl Tadalafil Figure 6)
This text provides information on the change from baseline in IPSS (International Prostate Symptom Score) total score after a 12-week treatment with Tadalafil 5 mg compared to placebo. The statistical significance (p<0.01) indicates a meaningful difference between the two groups. This data can be valuable for assessing the effectiveness of Tadalafil in managing lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).*
Spl-tadalafil-figure-8 (Spl Tadalafil Figure 8)
This text provides information on the change from baseline in the International Prostate Symptom Score (IPSS) total score after treatment with Tadalafil 5 mg and placebo. The data shows a statistically significant difference (* p<0.01) between the two treatment groups. Information on the duration of treatment in weeks is also presented.*
Spl-tadalafil-structure (Spl Tadalafil Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
